Molecular PCR • ABR • Treatment Guidance

Promus Pathway

The Promus Pathway uses proprietary technology to detect, identify, and diagnose complex multi-organism UTIs — all in less than 24 hours.1

Promus Pathway Revolutionizes the Way Clinicians Diagnose & Treat Urinary Tract Infections

Traditional culture-based methods require 72 hours (or more) to identify organisms and determine their susceptibility to various antibiotics. While awaiting results, the patient typically begins empirical antibiotic treatment — which may need to be revised based on results. The provider’s decision to treat empirically often leads to “antibiotic resistance,” a serious global health concern.
To reduce turn-around time, highly advanced labs have begun using molecular PCR analysis to identify pathogens in under 24 hours. However, labs using PCR to identify pathogens still must culture the sample to determine Colony Forming Units (CFUs) — the critical piece of information practitioners use to develop the appropriate prescription and treatment duration.
How is Promus Pathway Different?
Promus Pathway solves this critical issue using a proprietary technology and testing process that identifies pathogens, tests for antibiotic resistance genes, and provides treatment guidance in standard Colony Forming Units (CFUs) — all in less than 24 hours.
The combination of speed and accuracy empowers clinicians with the resources to prescribe the best possible antibiotic — true antibiotic stewardship.

In less than 24 hours1:

Detect & Identify

Rapid detection and identification of multi-organism infections.

Antibiotic Resistance

Real-time identification of 22 antibiotic resistance genes

Treatment Guidance

Colony Forming Units (CFUs)  report aids in treatment protocol and duration

One Panel. Multiple Organisms.

Promus Pathway detects bacterial, fungal, and viral pathogens simultaneously — ensuring any polymicrobial infections are identified. Promus Pathway detects over 97% of uropathogens compared to 65% using traditional urine culture methods. In addition to improved pathogen sensitivity that allows for the detection of just a single cell of a given organism, Promus Pathway identifies antibiotic resistance markers that are essential in determining the right antibiotic to eradicate infection.
Many polymicrobial infections are missed in routine culture due to overcrowded growth that makes analysis impossible. These cultures are terminated and reported as “Mixed Urogenital Flora” in typical microbiology lab reports. But the Promus Pathway ultra-sensitive PCR technology can detect and identify multiple organisms simultaneously, allowing for the rapid diagnosis of polymicrobial infections. 
From a clinician’s standpoint, polymicrobial infections are important to diagnose in their entirety as the treatment and management may become more complicated if only a portion of the infection is treated.

24 Hour Turn-Around

Results delivered within 24 hours of lab receiving the sample

Single-Cell Sensitivity

Promus Pathway can detect infection when only a single cell is present

Polymicrobial Infection

Simultaneous detection and identification of up to 31 different pathogens

End to End Service

24/7 Results Portal

Access results electronically 24/7 in our real-time portal

Treatment Guidance

What separates Promus Pathway from other PCR tests available in the market is our proprietary technology that detects infection, identifies the pathogens and antibiotic resistance markers, and provides treatment guidance in Colony Forming Units (CFUs) — all in one single-step process.

Other labs using PCR to identify urinary tract infections still must culture the sample to determine CFUs – the critical piece of information practitioners use to develop the appropriate prescription and treatment duration.

Promus Diagnostics has developed a proprietary process that enables us to report CFUs without the need to wait for culture. The result? — Practitioners can begin the correct treatment protocol sooner and with the confidence that the treatment with successfully eradicate the infection.

Clinically Significant Pathogens
Antimicrobial Resistance Markers

Target Pathogens

  • Acinetobacter baumannii
  • Actinobaculum schaalii
  • Aerococcus urinae
  • Candida albicans
  • Candida auris
  • Candida glabrata
  • Candida parapsilosis
  • Citrobacter freundii
  • Citrobacter koseri
  • Coagulase Negative Staph
  • Corynebacterium riegelii
  • Enterobacter aerogenes
  • Enterobacter cloacae
  • Enterococcus faecalis
  • Enterococcus faecium
  • Escherichia coli
  • Klebsiella oxytoca
  • Klebsiella pneumoniae
  • Morganella morganii
  • Mycoplasma hominis
  • Pantoea agglomerans
  • Proteus mirabilis
  • Proteus vulgaris
  • Providencia stuartii
  • Pseudomonas aeruginosa
  • Serratia marcescens
  • Staphylococcus aureus
  • Streptococcus agalactiae
  • Ureaplasma urealyticum
  • Viridans Group Strep

ABR Detection (Classifications)

  • ampC (Class C beta-lactamase)
  • DHA (Class C beta-lactamase)
  • IMP-1 group, IMP-16, IMP-7 (Class B metallo-beta-lactamase)
  • OXA-23, OXA-72, OXA-40, blaOXA-48 (Class D beta-lactamase)
  • VIM (Class B metallo-beta-lactamase)
  • CTX-M group 1, CTX-M group 2, CTX-M group 9, CTX-M group 8/25 (Class A Extended-Spectrum beta-lactamase)
  • OXA-1, GES (Class D, Class A beta-lactamase)
  • PER-1, PER-2 (Class A Extended-Spectrum beta-lactamase)
  • TEM (Class A Extended-Spectrum beta-lactamase)
  • mecA (Beta-lactam Methicillin)
  • QnrA, QnrS, QnrB (Quinolone Genes)
  • vanA1, vanA2, vanB (Vancomycin Genes)
  • dfrA5, dfrA1 (Trimethoprim Genes)
  • nfsA (Nitrofurantoin Genes)
  • FOX (Class C beta-lactamase)
  • ACC (Class C beta-lactamase)
  • MOX/CMY (Class C beta-lactamase)
  • BIL/LAT/CMY (Class C beta-lactamase)
  • SHV (Class A beta-lactamase)
  • VEB (Class A ESBL)
  • KPC (Class A beta-lactamase)
  • Sul1, Sul2 (Sulfonamide Genes)
  1. 24 hour turn-around-time based on when the lab receives the sample